Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tdap Vaccine Safety and Antibody Response in Plasma Donors
NCT05662852Phase 2Completed
- Sponsor
- ABO Holdings, Inc.
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine in Tetanus, diphtheria, pertussis, sponsored by ABO Holdings, Inc.. Started May 2023; status: completed.
02
Drugs
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine
03
Conditions
Tetanusdiphtheriapertussis
Beyond the preview
Go deeper on NCT05662852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662852.